(MLTX) MoonLake Immunotherapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.292m USD | Total Return: -52.8% in 12m
Avg Turnover: 12.9M
Warnings
Interest Coverage Ratio -26.5 is critical
Altman Z'' -6.13 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotechnology firm headquartered in Switzerland, specializing in immunology. The company’s primary focus is the development of Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F. This therapeutic candidate targets several chronic inflammatory conditions, including hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis.
The biotechnology sector often utilizes Nanobody technology because these smaller antibody fragments can potentially penetrate tissues more effectively than traditional monoclonal antibodies. MoonLake’s business model centers on advancing its single core asset through late-stage clinical trials to address unmet needs in dermatology and rheumatology. Detailed valuation metrics and pipeline comparisons are available via ValueRay for those conducting further due diligence. As a clinical-stage entity, the companys valuation is heavily driven by trial data readouts and the regulatory approval timeline for Sonelokimab.
- Phase 3 clinical trial results for Sonelokimab in hidradenitis suppurativa
- Regulatory approval timeline for Sonelokimab in psoriatic arthritis and dermatology
- Competitive landscape shifts within the IL-17 inhibitor therapeutic drug class
- Potential acquisition interest from large cap biopharmaceutical companies seeking immunology assets
- Capital requirements and cash runway to fund global late-stage clinical programs
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.58 > 0.02 and ΔFCF/TA -31.05 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.56 > 3% & CFO -224.2m > Net Income -257.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.3m) vs 12m ago 12.71% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: -26.54 > 6 (EBITDA TTM -249.0m / Interest Expense TTM 9.50m) |
| A: 0.88 (Total Current Assets 396.6m - Total Current Liabilities 46.1m) / Total Assets 400.4m |
| B: -1.33 (Retained Earnings -532.6m / Total Assets 400.4m) |
| C: -0.55 (EBIT TTM -252.1m / Avg Total Assets 455.8m) |
| D: -3.64 (Book Value of Equity -532.3m / Total Liabilities 146.3m) |
| Altman-Z'' = -6.13 = D |
As of May 24, 2026, the stock is trading at USD 18.47 with a total of 921,029 shares traded.
Over the past week, the price has changed by +3.65%,
over one month by +5.63%,
over three months by -2.62% and
over the past year by -52.77%.
MoonLake Immunotherapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MLTX.
- StrongBuy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.6 | 49.5% |
Revenue TTM = 0.0 USD
EBIT TTM = -252.1m USD
EBITDA TTM = -249.0m USD
Long Term Debt = 74.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 920k USD (from shortTermDebt, last quarter)
Debt = 102.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.61m
Net Debt = -252.4m USD (calculated: Debt 102.4m - CCE 354.8m)
Enterprise Value = 1.04b USD (1.29b + Debt 102.4m - CCE 354.8m)
Interest Coverage Ratio = -26.54 (Ebit TTM -252.1m / Interest Expense TTM 9.50m)
EV/FCF = -4.47x (Enterprise Value 1.04b / FCF TTM -232.4m)
FCF Yield = -22.36% (FCF TTM -232.4m / Enterprise Value 1.04b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.08m) / Revenue TTM)
Tobins Q-Ratio = 2.60 (Enterprise Value 1.04b / Total Assets 400.4m)
Interest Expense / Debt = 9.28% (Interest Expense 9.50m / Debt 102.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -199.2m (EBIT -252.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.32 (Total Current Assets 396.6m / Total Current Liabilities 74.5m)
Debt / Equity = 0.40 (Debt 102.4m / totalStockholderEquity, last quarter 254.0m)
Debt / EBITDA = 1.01 (negative EBITDA) (Net Debt -252.4m / EBITDA -249.0m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -252.4m / FCF TTM -232.4m)
Total Stockholder Equity = 300.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.40% (Net Income -257.1m / Total Assets 400.4m)
RoE = -30.87% (Net Income TTM -257.1m / Total Stockholder Equity 832.9m)
RoCE = -27.79% (EBIT -252.1m / Capital Employed (Equity 832.9m + L.T.Debt 74.1m))
RoIC = -62.64% (negative operating profit) (NOPAT -199.2m / Invested Capital 317.9m)
WACC = 7.26% (E(1.29b)/V(1.39b) * Re(7.26%) + D(102.4m)/V(1.39b) * Rd(9.28%) * (1-Tc(0.21)))
Discount Rate = 7.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 8.02%
[DCF] Fair Price = unknown (Cash Flow -232.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.53 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.91 | Chg30d=-1.11% | Revisions=+33% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.93 | Chg30d=-0.27% | Revisions=+33% | Analysts=8
EPS current Year (2026-12-31): EPS=-4.32 | Chg30d=-16.20% | Revisions=+0% | GrowthEPS=-22.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.51 | Chg30d=+3.06% | Revisions=+20% | GrowthEPS=+18.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +33%